(Reuters) - An independent panel's interim analysis of Eli Lilly and Co's breast cancer drug abemaciclib showed the treatment did not meet the effectiveness criteria in a late-stage trial.
The panel recommended the trial continue through the first half of 2017, the company said on Wednesday.
If approved, abemaciclib is expected to compete with Pfizer Inc's breast cancer drug, Ibrance (palbociclib), which brought in over half a billion dollars in second-quarter sales.
The trial is designed to evaluate the safety and efficacy of abemaciclib, in combination with anti-estrogen drug fulvestrant, in patients with a form of advanced breast cancer.
Lilly, which said it remained optimistic the combination could benefit patients, is also evaluating abemaciclib as a single agent in refractory metastatic breast cancer in patients who have not derived enough benefit from prior treatments.
Three other studies are testing abemaciclib with other drugs for various forms of breast cancer.
The drug, which was granted the U.S. Food and Drug Administration's (FDA) breakthrough therapy status for breast cancer last year, is also being tested for use in lung cancer.
After skin cancer, breast cancer is the most common cancer among women in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC).
About 40,000 of the 220,000 American women diagnosed with breast cancer die each year, the agency estimates.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου